Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies



Status:Recruiting
Conditions:Anemia, Anemia, Hematology, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:Any - 55
Updated:9/27/2018
Start Date:September 2, 2014
End Date:August 2021
Contact:Kim Nelson
Email:knelso62@fairview.org
Phone:612-273-2925

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders

This is a study to collect the outcomes of stem cell transplantation for patients with
hematologic diseases other than cancer.


Inclusion Criteria:

- Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other
non-malignant hematologic disorders for which a stem cell transplant is indicated

- Acceptable stem cell source identified

- Performance status of ≥ 70% (Karnofsky),or ≥ 70 (Lansky play score)

- Creatinine <2.0 mg/dl for adults or glomerular filtration rate > 50 ml/min for
children

- Bilirubin, Aspartate Aminotransferase, Alkaline phosphatase <5 times the upper limit
of institutional normal

- Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left
ventricular ejection fraction > 40%

Exclusion Criteria:

- active, uncontrolled infection

- pregnant or breastfeeding

- HIV positive
We found this trial at
1
site
University of Minnesota Medical Center, Fairview
2450 Riverside Ave
Minneapolis, Minnesota 55454
(612) 273-3000
Phone: 612-273-2925
University of Minnesota Medical Center, Fairview Improving patients' lives drives the innovation that makes University...
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials